FindTrial
Sign In

V001-BCMA

DRUG2 trials

Sponsors

Tongji Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Advanced Malignant TumoursRecurrent or Refractory ANCA Associated VasculitisRecurrent or Refractory Idiopathic Inflammatory MyopathyRecurrent or Refractory IgG4 Related DiseasesRecurrent or Refractory Systemic Lupus ErythematosusRecurrent or Refractory Systemic Sclerosis

Early Phase 1

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Active, not recruitingNCT07339540
Tongji HospitalRecurrent or Refractory ANCA Associated Vasculitis, Recurrent or Refractory Idiopathic Inflammatory Myopathy, Recurrent or Refractory IgG4 Related Diseases +2
Start: 2025-11-04End: 2028-10-30Target: 45Updated: 2026-09-17
A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening
RecruitingNCT07395479
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdvanced Malignant Tumours
Start: 2025-11-21End: 2027-12-01Target: 50Updated: 2026-05-13